177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation-Reference-Cited by-同舟云学术

177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

Published:2019-10-31 Issue:12 Volume:44 Page:978-980
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Assadi Majid,Pirayesh Elahe,Rekabpour Seyed Javad,Zohrabi Farshad,Jafari Esmail,Nabipour Iraj,Esmaili Abdolhamid,Amini Abdullatif,Ahmadzadehfar Hojjat

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Reference8 articles.

1. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis;Am J Nucl Med Mol Imaging,2016

2. PET/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer;Clin Nucl Med,2017

3. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT;Clin Nucl Med,2017

4. 68Ga-DOTATOC and 68Ga-PSMA PET/CT unmasked a case of prostate cancer with neuroendocrine differentiation;Clin Nucl Med,2016

5. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA positive metastatic large cell neuroendocrine prostate tumor;Clin Nucl Med,2019

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. Small cell neuroendocrine prostate cancer with adenocarcinoma components—case report and literature review;Translational Andrology and Urology;2024-05

3. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective;Cancers;2024-04-25

4. Dual 177Lu–Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation;Clinical Nuclear Medicine;2024-02-26

5. Production of the state of the art therapeutic radiopharmaceuticals in Iran, from beta- to alpha-emitting targeted radionuclide therapy: Clinical advances and perspectives;IRAN J NUCL MED;2024